Current Report Filing (8-k)
November 29 2016 - 4:56PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 OR 15(d)
of The Securities Exchange Act Of 1934
Date of report (Date of earliest event reported): November 27, 2016
ILLUMINA, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35406
|
|
33-0804655
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5200 Illumina Way, San Diego, CA
|
|
|
|
92122
|
|
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
Registrants telephone number, including area code: (858) 202-4500
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On November 27, 2016, Tristan Orpin, Executive Vice President, Clinical Genomics, notified Illumina, Inc. that he would be leaving the company in January
2017. Illumina has identified and agreed to employment terms with a successor to Mr. Orpin, who will join the company in January 2017.
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Illumina, Inc.
|
|
|
By:
|
|
/s/ Charles E. Dadswell
|
|
|
Charles E. Dadswell
|
|
|
Senior Vice President and General Counsel
|
Date: November 29, 2016
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Sep 2023 to Sep 2024